Showing results (11-20 of 22) with videos related to
Sort By:
Pageof 3
Cancers|February 15, 2022
Functional Therapeutic Target Validation Using Pediatric Zebrafish Xenograft ModelsCharlotte Gatzweiler, Johannes Ridinger, Sonja Herter, et al.Neuro-Oncology Advances|February 3, 2025
Pediatric spinal high-grade glioma in the pediatric precision oncology registry INFORM: Identification of potential therapeutic targetsElke Pfaff, Kathrin Schramm, Mirjam Blattner-Johnson, et al.Journal of Personalized Medicine|December 23, 2020
Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated ROS1/NTRK-Fusion Positive Pediatric High-Grade GliomaLisa Mayr, Armin S Guntner, Sibylle Madlener, et al.JCO Precision Oncology|June 26, 2023
Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORMAnna-Elisa Heipertz, Kristian W Pajtler, Elke Pfaff, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2025
Investigation of DNA Damage Response Genes Validates the Role of DNA Repair in Pediatric Cancer Risk and Identifies SMARCAL1 as a Novel Osteosarcoma Predisposition GeneNinad Oak, Wenan Chen, Alise Blake, et al.Medrxiv : the Preprint Server for Health Sciences|June 4, 2025
Comprehensive investigation of DNA damage repair genes in children with cancer identifies SMARCAL1 as novel osteosarcoma predisposition geneNinad Oak, Wenan Chen, Alise Blake, et al.Acta Neuropathologica|October 11, 2025
Molecular characterization and clinical features of diffuse midline glioma in the pediatric precision oncology registry INFORMElke Pfaff, Kathrin Schramm, Mirjam Blattner-Johnson, et al.Nature|May 7, 2025
Oncogene aberrations drive medulloblastoma progression, not initiationKonstantin Okonechnikov, Piyush Joshi, Verena Körber, et al.NPJ Precision Oncology|December 27, 2022
Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORMHeike Peterziel, Nora Jamaladdin, Dina ElHarouni, et al.The Journal of Clinical Investigation|February 12, 2026
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastomaLisa Werr, Jana Boland, Josephine Petersen, et al.Pageof 3